24/11/25 | 10:05 pm | heart attack

Print

Heart attack risk underestimated in 45% of cases under existing screening methods: Study

A new study has found that existing cardiac screening tools may be failing to identify nearly 45 per cent of individuals who are actually at risk of suffering a heart attack. The findings point to gaps in current assessment methods that rely mainly on symptoms and risk-score calculations.

The research, led by scientists from Mount Sinai in the US, has been published in JACC: Advances. It assessed whether two commonly used tools — the atherosclerotic cardiovascular disease (ASCVD) risk score and a newer calculator known as PREVENT — accurately reflect the risk of heart attacks.

The team analysed data from 474 patients under the age of 66 who had no previous diagnosis of coronary artery disease. According to the findings, if these patients had been evaluated two days before they suffered their first heart attack, nearly half would not have been advised for preventive therapy or further testing under current ASCVD-based guidelines. The percentage rose to 61 per cent when the PREVENT calculator was applied.

Researchers also reported that 60 per cent of patients developed symptoms such as chest pain or breathlessness less than two days before the cardiac event, indicating that symptoms may appear too late to guide preventive intervention.

The authors noted that early detection of plaque buildup — rather than depending largely on symptoms and risk scores — could improve prevention. They suggested increased use of atherosclerosis imaging to identify “silent plaque” at an early stage.

-IANS

RELATED ARTICLES

11 hours ago | 101 Years of MNS

29 Nursing Cadets Commissioned as Lieutenants into Military Nursing Service

Twenty-nine nursing cadets of Batch IX of the College of Nursing, Army Hospital (Research & Referral), Delhi Cantonment, were commissioned as Lieutenants into the Military Nursing Service (MNS) today at a ceremony held at the hospital. Lieutenant...

12 hours ago | AstraZeneca

NIPER Raebareli, AstraZeneca partner to strengthen 25 clinical trial sites beyond metros

The National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, and AstraZeneca India on Wednesday signed a partnership to strengthen clinical research capabilities across 25 emerging research locations, expanding trial capacity b...

19 hours ago | doctors remove part of lung

Pope Leo diagnosed with cancer as doctors remove part of lung

Pope Leo was diagnosed with lung cancer after surgeons removed a part of his right lung on Tuesday, the Vatican said in a medical bulletin, marking a significant health setback for the 71-year-old pontiff. The pope has lung adenocarcinoma, a common ...